Hypoplastic left heart syndrome: From bedside to bench and back

Area of Science:

• Cardiology
• Developmental Biology
• Regenerative Medicine

Background:

• Hypoplastic Left Heart Syndrome (HLHS) is a severe congenital heart defect with historically high mortality.
• Advances like the Norwood operation have increased survival rates, enabling patients to reach adulthood.
• Despite improved survival, HLHS patients face significant comorbidities and a higher mortality risk than other single-ventricle conditions.

Purpose of the Study:

• To review current clinical challenges in HLHS patient care.
• To explore systems biology for understanding HLHS molecular mechanisms.
• To evaluate stem cells, gene therapy, and tissue engineering for improving HLHS outcomes.

Main Methods:

• Review of clinical management strategies for HLHS.
• Exploration of systems biology approaches to dissect HLHS.
• Assessment of induced pluripotent stem cells (iPSCs) as a translational model.
• Investigation of regenerative medicine techniques including cell, gene, and tissue engineering.

Main Results:

• The Norwood operation dramatically improved HLHS survival, shifting the paradigm from infancy to adulthood.
• HLHS survivors experience substantial comorbidities, necessitating ongoing clinical management.
• Systems biology offers insights into the complex molecular underpinnings of HLHS.
• iPSCs provide a viable model for studying HLHS and testing therapeutic interventions.

Conclusions:

• Improved survival for HLHS necessitates addressing associated comorbidities and refining long-term care strategies.
• Regenerative medicine approaches, including cell and gene therapy, hold promise for regenerating cardiac structures and enhancing outcomes.
• Further research into systems biology and stem cell applications is crucial for advancing HLHS treatment.
• Multidisciplinary care and innovative therapies are key to improving the quality of life and survival rates for HLHS patients.